J. C. Haney, B. Czito, D. Tyler, C. Mantyh, J. Migaly**, Durham, NC

J. Yeung, V. Kalff, R. Hicks, M. Michael, S. Ngan, Y. Taouk, A. C. Lynch, A. G. Heriot**, Melbourne, VIC, Australia

J. Huh, B. Oh, J. Joo, H. Kim**, Y. Kim, Gwangju, South Korea

N. West, K. Sutton, P. Ingeholm, W. Hohenberger, P. Quirke**, Leeds, West Yorkshire, United Kingdom; Copenhagen, Denmark; Erlangen, Germany

P. Matthiessen, R. Lindgren, O. Hallbook, J. Rutegard, R. Sjodahl**, Orebro, Sweden, Linkoping, Sweden; Umea, Sweden

H. C. Burkholder, H. R. Bailey, M. Snyder, M. Pidala**, Houston, TX

H. Youssef, C. Newman, K. Chandrakumaran, F. Mohamed, T. Cecil, B. Moran**,  Basingstoke, United Kingdom

Objectives: At the conclusion of this session, participants should be able to: (11) compare the role of single port to conventional laparoscopic approach to right sided colon resection; (12) learn intracorporeal procedure and transvaginal specimen extraction for right side colon cancer; (13) demonstrate that transvaginal extraction after a right hemicolectomy is a feasable and safe procedure; (14) describe how the rates of laparoscopic colectomy have changed over time, specifically before and after publication of the COST trial and identify the types of patients who are most likely to undergo laparoscopic colectomy for cancer; (15) consider the safety and feasibility of robotic rectal surgery; (16) recognize robotic-assisted laparoscopic surgery as an emerging technique in the surgical management of benign and malignant colorectal diseases involving the pelvis and compare intraoperative and short-term outcomes of robotic-assisted laparaoscopic surgery with those of more established techniques such as hand-assisted and conventional laparoscopic approaches; (17) compare the efficacy of robotic versus laparoscopic assisted total mesorectal excision; (18) compare perioperative outcomes and long term survival between Laparoscopic resection and open resection for rectal cancer patients and assess the safety and oncologic feasibility of laparoscopic assisted resection for rectal cancer; (19) learn how angle-resolved low-coherence interferometry (a/LCI) works in a clinical setting and have the capability of a/LCI to provide information that can assist in the management of colonic dysplasia and cancer; and (20) analyze safety of practices for resuming anticoagulant medications post polypectomy.

J. A. Waters, M. J. Guzman, D. J. Selzer, E. A. Wiebke, B. W. Robb, V. George**, Indianapolis, IN

G. Choi**, J. Park, K. Lim, Y. Jang, S. H. Jun, Daegu, South Korea

K. C. Russek, M. E. Franklin**, A. Alvarez, San Antonio, TX; Presented by: M. Franklin

J. D. Rea, M. M. Cone, B. S. Diggs, K. E. Deveney, K. C. Lu, D. O. Herzig**, Portland, OR

J. Kwak, S. Kim**, D. Son, J. Kim, S. Baek, J. Cho, Seoul, South Korea

C. B. Patel, M. Ragupathi, D. I. Ramos-Valadez, E. Haas**; Houston, TX; Presented by: E. Haas

J. P. Ricci, H. Abcarian, L. M. Prasad**, A. L. deSouza, A. Zimmern, S. Marecik, J. Park, Chicago, IL; Park Ridge, IL

S. Baik, M. Mutch, E. H. Birnbaum, J. W. Fleshman**, St. Louis, MO

C. Mantyh, N. Terry, Y. Zhu, A. Wax**, C. Guy, J. Migaly, J. Thacker, Durham, NC

M. Heyrosa, S. Thekkeurumbil, S. Eid, I. Khubchandani**, Allentown, PA

Objectives: At the conclusion of this session, participants should be able to: (21) describe diagnosis of paradoxical contractions of puborectalis; (22) demonstrate the results of Prospective Multicenter Trial using Echodefecography for the assessment of Obstructed Defecation; (23) evaluate recurrence rates following rectopexy and no rectopexy for external full-thickness rectal prolapsed; (24) comprehend indications for STARR and be familiar with ODS patients, recurrence rates and the learning curve of this procedure; (25) analyze the cost benefit ratio of using STARR in treatment of obstructed defecation and comprehend the risk of recurrence after STARR and the effect of bio-feedback in recurrent cases; (26) appreciate the utility of sacral nerve stimulation in the treatment of fecal incontinence; (27) consider the long-term effectiveness and safety of sacral nerve stimulation in the treatment of fecal incontinence; (28) realize that sacral nerve stimulation carries a 40% rate of stimulator revision or replacement on the long term; (29) learn the potential of a new device to treat fecal incontinence by means of a magnetic anal sphincter; (30) comprehend the meaning of biofeedback therapy and its application for patients with anal incontinence and how to assess clinical improvement with it.

F. S. Regadas**, E. M. Haas, M. A. Abbas, J. M. Jorge, A. P. Habr-Gama, D. Sands, S. D. Wexner, I. M. Amaral, C. Sardinhas, D. M. Lima, U. E. Sagae, S. M. Murad-Regadas, Ceara, Brazil; Houston, TX; Los Angeles, CA; Sao Paulo, Brazil; Weston, FL; Caracas, Venezuela; Parana, Brazil

J. Karas, S. Uranues, D. F. Altomare, S. Sokmen, Z. Krivokapic, J. Hoch, R. Bergamaschi**, Stony Brook, NY; Graz, Austria; Bari, Italy; Inciralti, Turkey; Belgrade, Serbia; Prague, Czech Republic

H. Bahna, L. K. Burns, P. Williamson, S. DeJesus, J. Gallagher, A. Ferrara**, R. Mueller, Orlando, FL; Presented by: L. Burns

K. Madbouly**, K. Abbas, A. Hussein, Alexandria, Egypt

J. Murphy, D. J. Boyle, K. Prosser, M. L. Gooneratne, N. S. Williams, C. L. Chan**, London, United Kingdom

A. Mellgren**, S. D. Wexner, J. A. Coller, G. Devroede, T. Hull, R. McCallum, M. Chan, J. Ayscue, A. S. Shobeiri, D. Margolin, M. England, H. Kaufman, W. J. Snape, E. Mutlu, H. K. Chua, P. Pettit, D. Nagle, R. Madoff, D. R. Lerew, Minneapolis, MN; Weston, FL; Burlington, MA; Fleurimont, QC, Canada; Cleveland, OH; Kansas City, KS; Hong Kong, China; Washington, DC; Oklahoma City; OK; New Orleans, LA; Ft. Worth, TX; Los Angeles, CA; San Francisco, CA; Chicago, IL; Jacksonville, FL; Boston, MA

J. Faucheron**, D. Voirin, B. Badic, Grenoble, France

S. Buntzen, P. A. Lehur**, S. McNevin, A. Mellgren, S. Laurberg, R. Madoff, Aarhus, Denmark; Nantes, France; Spokane, WA; Minneapolis, MN

Objectives: At the conclusion of this session, participants should be able to: (31) identify predictors of surgical site infections in inflammatory bowel disease and use the risk score to identify those at highest risk of SSI; (32) analyze the difference in patients undergoing surgery for Crohn's Disease pretreated with IFX or other immunosuppressor drugs and analyze potential differences in postoperative abdominal and pulmonary infections in all patients undergoing surgery for CD based upon use or absence of medical treatment; (33) learn the role of immunomodulators in patients with Crohn's like complications post IPAA; (34) comprehend the role of biologic immunomodulators in surgically treated perianal Crohn's fistulas; (35) learn a novel optical technique that can potentially improve the management for IBD; (36) consider the relationship between microbial ecology and the pathogenesis of ulcerative colitis and the technical achievements inherent in combining laser capture microdissection with PCR in the enumeration of bacteria, and comprehend the relationship between desulfovibrio bacterial species and ulcerative colitis; (37) realize the relationship between phenotype and genotype in patients with perianal Crohn's Disease; (38) correlate gene haplotypes with complications after IPAA; (39) use MR enterography as an additional tool in the assessment of patients with Crohn's disease and enteric strictures; and (40) discuss the oncologic outcomes of performing stapled IPAA vs. mucosectomy with hand-sewn IPAA.

K. Alavi, P. Sturrock, W. B. Sweeney**, J. A. Maykel, J. A. Cervera-Servin, E. F. Cook, Worcester, MA; Boston, MA

J. Canedo, R. Pinto, S. M. Murad-Regadas, S. Lee, L. Rosen, S. D. Wexner**, Weston, FL

L. Haveran, R. Sehgal, D. B. Stewart, K. McKenna, L. S. Poritz, W. Koltun**, Hershey, PA

G. El-Gazzaz, T. Hull, J. M. Church**, Cleveland, OH

X. Bi, A. Walsh, A. Mahadevan-Jansen, A. Herline**, Nashville, TN

J. C. Coffey, F. Rowan, N. Docherty, B. Murphy, P. R. O’Connell**, Dublin, Ireland

S. Dharmarajan, G. Nandakumar, R. A. Busch, C. Hamm, E. Li, S. Hunt**, St. Louis, MO

R. Sehgal, A. Berg, J. Hegarty, A. Kelly, Z. Lin, L. Poritz, W. Koltun**, Hershey, PA

E. Messaris, D. Grand, B. Winn, M. Resnick, V. Pricolo**, Providence, RI

W. Al-Sukhni, R. McLeod, H. MacRae, B. O’Connor, H. Huang, Z. Cohen**, Toronto, ON, Canada

Objectives: At the conclusion of this session, participants should be able to: (41) assess the value of distal marging in rectal cancer surgery; (42) determine the safety of distal resection margin when performing radical resection for low rectal cancer; (43) decide whether to use the absolute positive lymph node count or lymph node ratio as a prognostic tool in rectal cancer patients after neo-adjuvant chemo-radiation followed by total mesorectal excision; (44) comprehend the relationship between lymph node harvest and patient outcomes and survival and consider these results when staging patients and ultimately deciding on treatment options, especially in stage II colorectal cancer; (45) recognize the difficulty using standard stains to identify lymphatic vessels, identify differences in lymphatic characteristics within layers of the bowel wall and learn the potential prognostic value of lymphatic vessel characteristics in T1 colorectal tumors; (46) evaluate several markers in the apoptotic pathway as well as expression of COX-2 and VGEF to determine their ability to predict response to CMT; (47) evaluate the effectiveness of tailored-chemotherapy based on ATP-CRA in patients with liver metastasis from colorectal cancer; (48) comprehend the significance of mismatch repair status in terms of treatment and prognosis; (49) evaluate the oncologic implications of acellular mucin in resected rectal cancers with pathologic complete response to neoadjuvant chemoradiation; and (50) recognize diagnostic criteria for hyperplastic polyposis syndrome, define colorectal cancer risk associated with this syndrome and consider the need for surveillance and indications for colectomy in this syndrome.

A. Rutkowski**, M. Chwalinski, J. Oledzki, K. Bujko, M. Bednarczyk, P. Liszka Dalecki, A. Gornicki, Warsaw, Poland

C. L. Klos, L. Bordeianou, P. Sylla, Y. Chang, D. L. Berger**, Amsterdam, Netherlands; Boston, MA

C. E. Peeples**, J. Shellnut, H. Wasvary, J. Sacksner, Royal Oak, MI

K. J. Smith, D. A. Burke, P. Finan, P. Jones, P. Quirke**, Leeds,West Yorkshire, United Kingdom

T. Kim, H. Hur, B. Min, K. Lee, N. Kim**, Seoul, South Korea

Y. S. Yoon, C. S. Yu, J. C. Kim**, Seoul, South Korea

L. de Campos-Lobato, M. F. Kalady**, D. Dietz, L. Stocchi, J. D. Vogel, I. C. Lavery, Cleveland, OH

M. F. Kalady**, A. M. Jarrar, L. LaGuardia, M. O’Malley, B. Leach, C. Eng, J. M. Church, Cleveland, OH

Objectives: At the conclusion of this session, participants should be able to: (51) learn about a new ambulatory surgical technique used to treat low degree, symptomatic hemorrhoids and recognize pros and cons of two different mini-invasive treatments for hemorrhoids; (52) comprehend ALTA, a novel sclerosing agent for noninvasive treatments of internal hemorrhoids and prolapsed; (53) discuss the outcomes, advantages, and disadvantages of doppler guided hemorrhoidectomy; (54) carefully select patients for surgical treatment for hemorrhoidal disease; (55) learn the Ligation of Intersphincteric Fistula Tract for the treatment of Fistula in Ano; (56) learn how to use topical sucralfate for wounds around the anus to hasten healing and reduce inflammation; (57) realize the difference in healing rate, fecal incontenence and sexual function between episioproctotomy and mucosal advancement flap in treatment of obestetric and cryptogenic rectovaginal fistulas; (58) discuss the recurrence rate after an initial attack of complicated diverticulitis and the risk factors for a recurrent attack of diverticulitis; (59) understand nonoperative management strategies and their efficacy in acute perforated diverticulitis; and (60) comprehend the factors associated with mortality in Clostridium difficile colitis.

M. Takano**, J. Iwadare, H. Takamura, Y. Matsuda, S. Tsuchiya, Kumamoto, Japan; Tokyo, Japan; Amagasaki, Japan; Hamamatsu, Japan; Yokohama, Japan

C. Helmes, F. Pakravan**, B. Meshkat, H. Abcarian, Duesseldorf, Germany; Dublin, Ireland; Chicago, IL

P. J. Gupta**, P. S. Heda, S. Kalaskar, Nagpur, Maharashtra, India

G. El-Gazzaz, T. Hull**, M. Zutshi, J. M. Church, B. Gurland, Cleveland, OH

J. F. Hall**, P. L. Roberts, R. Ricciardi, T. Read, P. W. Marcello, C. Wald, D. J. Schoetz, Burlington, MA

S. Dharmarajan, S. Hunt, E. H. Birnbaum, J. W. Fleshman, M. Mutch**, St. Louis, MO

G. Nandakumar, S. Dharmarajan, C. Coughlin, C. Menias, M. Ray, S. Hunt**, St. Louis, MO; Davis, CA

Objectives:  At the conclusion of this session, participants should be able to: (61) adopt an enhanced recovery program in patients undergoing laparoscopic resection for colon cancer and develop an adequate enhanced recovery program in their circumstances; (62) identify the risk factors for prolonged length of stay after colorectal surgery; (63) assess whether inequalities in demographics and socioeconomic status affect patient length of stay following colon and rectal surgery; (64) learn current trends of colorectal cancer incidence in different age groups, compare trends of colorectal cancer to cervical cancer and learn the distribution of colorectal cancers in patients between the ages of 35 and 49; (65) recognize the increased mortality and morbidity in dialysis patients undergoing colorectal surgery and recognize that urgent/emergent colorectal procedures in dialysis patients are associated with a 25% mortality; (66) recognize the underuse of chemotherapy amongst stage 3 colorectal cancer patients and realize the association between adverse events and omission of stage-appropriate chemotherapy; (67) comprehend venous thromboembolism rates in colorectal surgery patients and be aware of the risk of venous thromboembolism after hospital discharge in colorectal surgery patients; (68) realize several options for preoperative antibiotic preparation prior to elective colon resection and assess the role of preoperative oral antibiotic use on surgical site infections; (69) analyze the outcome of patients operated-on for diseases of the left colon in emergency conditions, when a resecction with primary anastomosis was performed without intraoperative colonic irrigation; and (70) realize that lymphatic invasion was an independent predictive factor of recurrence in patients with pSM CRC and that considering the survival benefit and cost performance for relapsed patients, postoperative intensive follow up for patients with pT1 CRC may be unnecessary.

T. Lee, S. Kang**, S. Hong, D. Kim, Seongnam-si, Gyeonggi-do, South Korea; Presented by: S. Kang

L. de Campos-Lobato, E. Wick, P. R. Kiran, F. Remzi, J. D. Vogel**, Cleveland, OH; Baltimore, MD

S. L. Stein, J. Rose, B. J. Champagne, P. Knoll, H. Reynolds, B. J. Ermlich, J. Stulberg, C. P. Delaney**, Cleveland, OH

D. M. Davis, J. Mateka, J. Marcet**, V. Nfonsam, J. Frattini, Tampa, FL

S. Drolet, A. M. Shaheen, R. P. Myers, E. Dixon, A. R. MacLean, W. D. Buie**, Calgary, AB, Canada

S. K. Hendren, J. Birkmeyer, C. Sonnenday, H. Yin, M. Banerjee, A. M. Morris**, Ann Arbor, MI

F. Fleming, M. J. Kim, R. Salloum, J. R. Monson**, Rochester, NY

K. I. El-Badawi, T. Asgeirsson, C. Mascarenhas, S. Suryadevara, R. Hoedema, D. G. Kim, M. Luchtefeld, A. Senagore**, Grand Rapids, MI

M. Ciga**, F. Oteiza, L. Fernández-Rico, J. Marzo, P. Armendáriz, M. De Miguel, H. Ortiz, Pamplona, Spain

S. Lida, H. Hasegawa**, Y. Ishii, T. Endo, K. Okabayashi, Y. Kitagawa, Tokyo, Japan

Martin Hubner, MD, Lausanne University Hospital, Lausanne, Switzerland

Joseph Plummer, MBBS, DM, University of the West Indies, Kingston, Jamaica

James O'Riordan, MD, Tallaght Hospital, Dublin, Ireland

John (Ian) Jenkins, MD, St. Mark's Hospital, London, England

Mr. Angus J. M. Watson, FRCS Ed, Department of Surgery, Raigmore Hospital, Inverness, Scotland

Tarik Sammour, MD, Department of Surgery, South Auckland Clinical School, University of Auckland, Auckland, New Zealand

Professor the Lord Darzi of Denham, PC, KBEHonFREng, FMedSci, Division of Surgery, St. Mary's Hospital Campus, Imperial College London, UK Global Health and Life Sciences Ambassador, London, United Kingdom; Funded by the Harry E. Bacon Foundation; Introduction: Matthew Mutch, MD

Honoring Stanley M. Goldberg, MD, FACS, HonFRACS (Aust), HonFRCS (Eng), HonAFC (Fr), HonFRCPS, (Glasg), HonFRSM (Eng), Hon FPCS (Phil), HonFRCS (Edin), Honoris Causa (Lleida), HonSAS (Spain), HonJSS (Japan); Speaker: Richard K. Reznick, MDMEd, FRCSC, FACS, R.S. McLaughlin Professor and Chair, Department of Surgery, University of Toronto, Vice-President of Education, University Health Network, Toronto, ON, Canada; Introduction: Michael Spencer, MD

Objectives: At the conclusion of this session, participants should be able to understand: a) the indications and uses for submucosal resection of colonic polyps; b) the indications, technical aspects and benefits of single incision laparoscopy; c) the indications, benefits, and barriers for the use of robotics in colon and rectal surgery; and d) the technology associated with and the potential uses and pitfalls of NOTES.

Objectives: At the conclusion of this session, participants should be able to: a) understand the basic concepts of clinical trials and how to get started; and b) learn of opportunities within the NIH and industry; and c) encourage clinical trial research on diseases of the colon, rectum and anus.

Objectives: Upon completion of this session, participants should be able to: a) describe the different techniques for stoma formation; and understand the treatment options for managing enterostomal complications; b) summarize the anatomical derangements that make the anoperineal skin susceptible to disease; and outline the etiologies and associated treatments of the benign dermatologic conditions affecting the anoperineum; c) demonstrate an understanding of the current management of rectovaginal and rectourethral fistula; d) demonstrate an understanding of the current controversies and medical management of Crohn's disease in the era of biologics; e) discuss the options and principles in the investigation of lower GI bleeding; and understand the principles and outcomes of the surgical management of lower GI bleeding; and f) demonstrate an understanding of the current management of rectal cancer including the use of neoadjuvant and adjuvant therapy.

Objectives: At the conclusion of this session, participants will be able to: a) understand the rationale and benefits of medical therapy in the treatment of Ileocolic Crohn's disease; b) discuss the role of biologics in the treatment of anorectal Crohn's disease; c) understand the risks, benefits, and selection of patients for the medical therapy of acute colitis; and d) select patients that might benefit from the use of aggressive medical maintenance therapy in the post-operative setting.

Objectives: At the conclusion of this session, participants should be able to understand: a) different laparoscopic approaches to mobilize the colon; b) techniques to manage intra-operative complications laparoscopically; c) techniques available to endoscopically resect large colonic polyps; and d) techniques available to manage complications such as GI bleeding and post-polypectomy perforation endoscopically.

Objectives: At the conclusion of this session, participants should be able to: a) provide mentoring and counseling to students, residents, colleagues, and staff; b) efficiently manage the wealth of information and technology that we are faced with in order to more effectively educate and communicate with our colleagues and patients; c) describe how our strengths and weaknesses impact our personal and professional lives; and d) discuss and counsel patients and families through difficult medical situations.

Objectives:  At the end of this session, surgeons should be better able to understand: a) the current status of EBRS in colorectal surgery; b) the various methods of incorporating EBRS into training programs as well as clinical practice; and c) how to run a journal club.

Objectives: At the conclusion of this session, participants should be able to: (SV1) analyze the anatomy and technical tips of laparoscopic approaches for rectal prolapse; (SV2) demonstrate the resection of full thickness prolapse of the rectum by stapler device; (SV4) learn a new procedure for treating fecal incontinence; (SV5) comprehend the steps involved in performing an ACE procedure; (SV6) learn the technique for excision of pilonidal disease using the Karydakis flap; (SV7) learn about a new, bioabsorbable product, the BIO-A Fistula Plug developed by W. L. GORE design for anal fistula treatment; (SV8) describe the technique for performing a BioLIFT procedure and discuss the outcomes of patients whose fistula is managed with the BioLIFT procedure; and (SV9) realize that Transanal Endoscopic Microsurgery has a definite role in treatment of complex benign anorectal diseases and that offers significant advantages compared to more traditional surgical techniques in selected patients.

B. Feng, M. Zheng, J. Yan, J. Kawamura, W. Lei, O. Olival, R. Pavoor, J. Milsom, Shanghai, China; New York, NY (V-8); Presented by J. Milsom

L. Williams, D. Trottier, E. Davenport, R. Boushey, E. Poulin, J. Mamazza, Ottawa, ON, Canada (OV-15)

M. Zutshi, B. Gurland, T. Hull, Cleveland, OH (V-11)

P. Ferreira, B. Gurland, M. Zutshi, R. Rackley, T. Hull, Cleveland, OH (V-12); Presented by: B. Gurland

S. Suryadevara, M. Luchtefeld, D. Kim, Grand Rapids, MI (V-14)

C. Bouchard, N. Mantilla Farfan, H. Abcarian, M. Singer, Chicago, IL; Evanston, IL (V-17)

R. Pigalarga, N. Maloney Patel, C. Rezac, New Brunswick, NJ (V-21)

S. Marecik, C. Bouchard, L. Prasad, V. Chaudhry, Park Ridge, IL and Chicago, IL (OV-21)

Objectives:  At the conclusion of this session, participants should be able to: (TV1) comprehend the pelvic and perineal anatomy in order to improve the quality of abdominoperineal resection; (TV2) learn more about cylindrical APR; (TV9) discuss about surgical approach to pelvic recurrence from rectal cancer and techniques to reconstruct the pelvic floor; and (TV10) learn the technique of en bloc abdominoperineal resection with vaginectomy for gastrointestinal tumor (GIST) of rectovaginal septum with anal sphincter involvement and consider the technique for perineal and neovaginal reconstruction using rectosigmoid flap.

H. Acar, A. Aslar, M. Kuzu, Ankara, Turkey (V-3); Presented by: M. Kuzu

N. Brindzei, A. Demercurio, E. Breen, J. Goldberg, R. Bleday, Boston, MA (V-25)

M. Bun, A. Canelas, B. Helman, M. Laporte, C. Peczan, N. Rotholtz, Buenos Aires, Argentina (OV-5)

J. Marks, R. Essani, E. Larkin, Wynnewood, PA (OV-20)

L. Prasad, S. Marecik, A. deSouza, J. Ricci, J. Park, Park Ridge, IL; Chicago, IL (OV-24)

S. Marecik, A. deSouza, J. Ricci, J. Park, L. Prasad, Park Ridge, IL and Chicago, IL (OV-25)

K. Umanskiy, J. Holder-Murray, M. Katdare, R. Hurst, A. Fichera, Chicago, IL (OV-27)

P. Delrio, U. Pace, D. Scala, F. Ruffolo, C. Sassaroli, F. Cremona, G. Nasti, G. Romano, Naples, Italy (V-28)

P. Atittharnsakul, C. Sahakitrungruang, Bangkok, Thailand (V-24)

Objectives:  At the conclusion of this session, participants should be able to: (WV1) identify a surgical approach to single incision approach to performing a right hemicolectomy and comprehend the steps of a SILS right hemicolectomy; (WV2) describe potential benefits and short-term outcomes of single incision laparoscopic surgery for sigmoid resection and recognize potential challenges in single incision laparoscopic sigmoidectomy as well as possible techniques to overcome these challenges; (WV3) learn where the minimum invasive surgery should face or make progress and recognize the importance of the remote controlled surgery by magnetic retraction; (WV4) develop technical tips to facilitate completion of a single incision laparoscopic colectomy; (WV9) identify therapeutic options for relief of anastomotic strictures and occlusions; and (WV10) comprehend the surgical technique of transanal endoscopic microsurgery and recognize an alternative method in performing a transanal endoscopic microsurgery.

D. Gandhi, C. Patel, D. Ramos-Valadez, M. Ragupathi, E. Haas, Houston, TX (V-9); Presented by E. Haas

V. Ho, J. DiRocco, J. Milsom, T. Sonoda, S. Lee, New York, NY (V-18)

D. Uematsu, G. Akiyama, Saku City, Nagano, Japan (V-19)

R. Makhija, B. Champagne, C. Delaney, Cleveland, OH (OV-6)

K. Garrett, D. Geisler, F. Remzi, Cleveland, OH (OV-12)

A. Canelas, M. Bun, B. Helman, M. Laporte, C. Peczan, N. Rotholtz, Buenos Aires, Argentina (OV-3)

A. Fajardo, S. Hunt, M. Frisella, J. Fleshman, M. Mutch, St. Louis, MO (OV-9)

E. Davenport, S. Zolfigari, L. Williams, R. Boushey, Ottawa, ON, Canada (OV-28)

C. Coco, A. Verbo, G. Rizzo, A. Manno, C. Mattana, M. Mastromarino, Rome, Italy (OV-1); Presented by A. Manno